Expansion of Probiotics Facility Strengthens DuPont’s Position as Leader in Probiotics Production
New enhancements increase capability for rapidly developing and commercializing new probiotics with decreased time to market.
DuPont Nutrition & Health (DuPont) has announced a substantial upgrade to its probiotics pilot facility in Madison, Wisconsin. The $10 million investment strengthens and emboldens DuPont’s current impressive position as a leader in the probiotics industry, allowing for increased pace of new product development and significantly improved delivery times on pilot material for clinical trials and customer evaluations.
Construction on the Madison probiotics pilot area, completed in phases over the last six months, provides increased capacity and speed for new product development. This in turn improves overall scale up capability and a more seamless transition to commercial scale production.
“Given the explosive rise in demand for probiotics products all around the globe, this project allows us to aggressively pursue our goal to be the No. 1 probiotics supplier in the world,” said DuPont Nutrition & Health President Matthias Heinzel. “These expansion efforts show our commitment to becoming bigger and stronger with our capability to meet demand, and our facilities, and qualified staff to handle the significant growth we foresee in this sector.”
The pilot area features new, state-of-the-art equipment, data collection, laboratories, instrumentation and specialized work space for probiotic development and scale up. The upgrades that quadrupled the pilot area have already increased bandwidth to simultaneously run more development projects while improving scale up efficiency and time to market.
“With all the enhancements, we are better able to meet customer demand for new probiotics at a much faster pace,” said Kurt Fenster, BioProcess Development group manager, Culture Manufacturing Technology at DuPont Nutrition & Health. “Moving forward, we expect to substantially increase our speed to deliver products to customers.”
DuPont Nutrition & Health combines in-depth knowledge of food and nutrition with current research and expert science to deliver unmatched value to the food, beverage and dietary supplement industries. We are innovative solvers, drawing on deep consumer insights and a broad product portfolio to help our customers turn challenges into high-value business opportunities. More information is available at www.food.dupont.com
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com
Merger of Equals
On August 4, 2017, DuPont and The Dow Chemical Company (“Dow”) announced that all required regulatory approvals and clearances had been received in connection with the proposed merger of equals pursuant to the Agreement and Plan of Merger, as amended on March 31, 2017, (the “Merger Agreement”) under which the companies will combine in an all-stock merger (the “Merger Transaction.”) Dow and DuPont have agreed in writing that the closing conditions have been satisfied and that the Merger Transaction will close on August 31, 2017.
Certain regulatory approvals and clearances were granted based on the companies fulfilling their commitments to divest certain assets, among other conditions, (the “Conditional Commitments”). In connection with the Conditional Commitments, DuPont entered into a definitive agreement (the “FMC Transaction Agreement”) with FMC Corporation (FMC). Under the FMC Transaction Agreement subject to the closing of the Merger Transaction in addition to customary closing conditions, including regulatory approval, FMC will acquire certain Crop Protection business and R&D assets from DuPont and DuPont has agreed to acquire certain assets relating to FMC’s Health and Nutrition segment, (collectively, the “FMC Transactions”). DuPont and Dow intend, following consummation of the Merger Transaction, that the combined company, DowDuPont Inc., will pursue, subject to the receipt of approval by the board of directors of DowDuPont, the separation of the combined company’s agriculture business, specialty products business, and materials science business through a series of tax-efficient transactions (collectively, the “Intended Business Separations”). For more information, please see DuPont’s latest annual, quarterly and current reports on Forms 10-K, 10-Q and 8-K, as well as the joint proxy/prospectus included in the DowDuPont Registration Statement on Form S-4 filed in connection with the Merger Transaction.
This document contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company’s strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures, financial results and timing of, as well as expected benefits, including synergies, from the Merger Transaction and the Intended Business Separations, are forward-looking statements. These and other forward-looking statements, including the failure to consummate the Merger Transaction, the Intended Business Separations, the FMC Transactions or the Conditional Commitments, to make or take any filing or other action required to consummate such transactions in a timely manner or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the Merger Transaction, the Intended Business Separations, the FMC Transactions and the Conditional Commitments. These risks, as well as other risks associated with the Merger Transaction, the Intended Business Separations, the FMC Transactions and the Conditional Commitments, are or will be more fully discussed in (1) DuPont’s most recently filed Form 10-K, 10-Q and 8-K reports, (2) DuPont’s subsequently filed Form 10-K and 10-Q reports and (3) the joint proxy statement/prospectus included in the Registration Statement filed with the SEC about the Merger Transaction. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, monetary loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. The company assumes no obligation to publicly provide revisions or updates to any forward-looking statements, whether because of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.